Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: The protective role of dexrazoxane

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 1, 2010, Pages 87-96

  Spallarossa, Paolo ^a   Altieri, Paola ^a   Pronzato, Paolo ^b   Aloi, Concetta ^a   Ghigliotti, Giorgio ^a   Barsotti, Antonio ^a   Brunelli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; ANTIBODY; BETA GALACTOSIDASE; EPIRUBICIN; ERBB2 ANTIBODY; F ACTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROPIDIUM IODIDE; PROTEIN KINASE B; RAZOXANE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL AGING; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; FETUS; HEART MUSCLE CELL; HEART PROTECTION; MITOCHONDRIAL MEMBRANE POTENTIAL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; STAINING; SURVIVAL; THERAPY EFFECT;

ACTINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARDIOTONIC AGENTS; CELL CULTURE TECHNIQUES; CELL DEATH; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EPIRUBICIN; GLYCOPROTEINS; IMMUNOBLOTTING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE;

EID: 73949096812     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.159525     Document Type: Article

References (40)

1. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL, Schreiber K, Rindt H, Gorczynski RJ, and Olson EN (2003) Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 278:28930-28937.
2. Ben-Porath I and Weinberg RA (2004) When cells get stressed: an integrative view of cellular senescence. J Clin Invest 113:8-13.
3. Bria E, Cuppone F, Fornier M, Nisticò C, Carlini P, Milella M, Sperduti I, Terzoli E, Cognetti F, and Giannarelli D (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat 109: 231-239.
4. Brown SB, Bailey K, and Savill J (1997) Actin is cleaved during constitutive apoptosis. Biochem J 323:233-237.
5. Chen X, Wilson RM, Kubo H, Berretta RM, Harris DM, Zhang X, Jaleel N, Mac-Donnell SM, Bearzi C, Tillmanns J, et al. (2007) Adolescent feline heart contains a population of small, proliferative ventricular myocytes with immature physiological properties. Circ Res 100:536-544.
6. Chuang TC, Liu JY, Lin CT, Tang YT, Yeh MH, Chang SC, Li JW, and Kao MC (2007) Human manganese superoxide dismutase suppresses HER2/neu-mediated breast cancer malignancy. FEBS Lett 58:4443-4449.
7. Damen CW, Rosing H, Schellens JH, and Beijnen JH (2008) Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry. J Pharm Biomed Anal 46:449-455.
8. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, and Pereira-Smith O (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92:9363-9367.
9. Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, Sohn S, Kim WH, Yoon G, and Choi KS (2005) Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24:4765-4777.
10. Ewer MS and Benjamin RS (2000) Cardiac complications, in Cancer Medicine (Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, and Gansler TS, eds), 5th ed, pp 2324-2339, Williams & Wilkins, Baltimore.
11. Ewer SM and Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31:459-467.
12. Ewer MS and Tan-Chiu E (2007) Reversibility of trastuzumab cardiotoxicity: is the concept alive and well? J Clin Oncol 25:5532-5533.
13. Furukawa Y, Nishimura N, Furukawa Y, Satoh M, Endo H, Iwase S, Yamada H, Matsuda M, Kano Y, and Nakamura M (2002) Apaf-1 Is a Mediator of E2F-1-induced Apoptosis. J Biol Chem 42:39760-39768.
14. Gabrielson K, Bedja D, Pin S, Tsao A, Gama L, Yuan B, and Muratore N (2007) Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res 67:1436-1441.
15. Gerland LM, Peyrol S, Lallemand C, Branche R, Magaud JP, and Ffrench M (2003) Association of increased autophagic inclusions labeled for beta-galactosidase with fibroblastic aging. Exp Gerontol 38:887-895.
16. Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, Naik TJ, Prasad SV, and Ardehali H (2009) Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 284:2080-2087.
17. Halliwell B (2000) The antioxidant paradox. Lancet 355:1179-1180.
18. Kanakry CG, Li Z, Nakai Y, Sei Y, and Weinberger DR (2007) Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer. PLoS ONE 2:e1369.
19. Konorev EA, Vanamala S, and Kalyanaraman B (2008) Differences in doxorubicin-induce apoptotic signaling in adult and immature cardiomyocytes. Free Radic Biol Med 45:1723-1728.
20. Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Khai NC, Maruyama R, Ogino A, et al. (2006) Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 113:535-543.
21. Lu L, Wu W, Yan J, Li X, Yu H, and Yu X (2009) Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure Int J Cardiol 134:82-90.
22. Maejima Y, Adachi S, Ito H, Hirao K, and Isobe M (2008) Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 7:125-136.
23. Malisza KL and Hasinoff BB (1996) Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells. Free Radic Biol Med 20:905-914.
24. Menna P, Salvatorelli E, and Minotti G (2008) Cardiotoxicity of antitumor drugs. Chem Res Toxicol 21:978-989.
25. Pentassuglia L, Graf M, Lane H, Kuramochi Y, Cote G, Timolati F, Sawyer DB, Zuppinger C, and Suter TM (2009) Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res 315:1302-1312.
26. Pugatsch T, Abedat S, Lotan C, and Beeri R (2006) Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Res 8:R35.
27. Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggiò MA, Mordente A, Gianni L, and Minotti G (2006) Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem 281:10990-11001.
28. Sharpless NE and DePinho RA (2004) Telomeres, stem cells, senescence, and cancer. J. Clin. Invest 113:160-168.
29. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
30. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, Fabbi P, Ballestrero A, Brunelli C, and Barsotti A (2006) Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69:736-745.
31. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F, et al. (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37:837-846.
32. Takemura G, Miyata S, Kawase Y, Okada H, Maruyama R, and Fujiwara H (2006) Autophagic degeneration and death of cardiomyocytes in heart failure. Autophagy 2:212-214.
33. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, et al. (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer. NSABP B-31. J Clin Oncol 23:7811-7819.
34. Tauszig-Delamasure S, Yu LY, Cabrera JR, Bouzas-Rodriguez J, Mermet-Bouvier C, Guix C, Bordeaux MC, Arumäe U, and Mehlen P (2007) The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm. Proc Natl Acad Sci U S A 104:13361-13366.
35. Terman A, Dalen H, Eaton JW, Neuzil J, and Brunk UT (2004) Aging of cardiac myocytes in culture: oxidative stress, lipofuscin accumulation, and mitochondrial turnover. Ann N Y Acad Sci 1019:70-77.
36. Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, Suter TM, and Zuppinger C (2006) Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 41:845-854.
37. Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y, and Maehara Y (2007) Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat 101:249-257.
38. van Dalen EC, Caron HN, Dickinson HO, and Kremer LCM (2008) Cardioprotective interventions for cancer patients receiving anthracyclines (2008) Cochrane Database Syst Rev 2:CD003917.
39. Xiang P, Deng HY, Li K, Huang GY, Chen Y, Tu L, Ng PC, Pong NH, Zhao H, Zhang L, et al. (2009) Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model Cancer Chemother Pharmacol 63:343-349.
40. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, and Hung MC (2000) HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275:8027-8031.